De novo mutations in SMCHD1 cause Bosma arhinia microphthalmia syndrome and abrogate nasal development by Gordon, C et al.
 RADAR 
Research Archive and Digital Asset Repository 
 
 
 
Gordon, C., et al. (2017) 'De novo mutations in SMCHD1 cause Bosma arhinia microphthalmia syndrome and 
abrogate nasal development', Nature Genetics, 49 (2), pp. 249-255. 
 
DOI: https://doi.org/10.1038/ng.3765 
 
 
This document is the authors’ Accepted Manuscript. 
License: https://creativecommons.org/licenses/by-nc-nd/4.0  
Available from RADAR: https://radar.brookes.ac.uk/radar/items/675185cd-87f6-4d0a-8f7c-06f3ab207abd/1/ 
 
 
Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners unless otherwise waved in 
a license stated or linked to above. A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially 
in any format or medium without the formal permission of the copyright holders. 
1 
 
De novo mutations in SMCHD1 abrogate nasal 1 
development 2 
 3 
Christopher T. Gordon1,2*, Shifeng Xue3,4*, Gökhan Yigit5*, Hicham Filali1,2,6*, Kelan 4 
Chen7,8*, Nadine Rosin5, Koh-ichiro Yoshiura9, Myriam Oufadem1,2, Tamara J. Beck7, 5 
Ruth McGowan10, Alex C. Magee11, Janine Altmüller12,13,14, Camille Dion15, Holger 6 
Thiele12, Alexandra D. Gurzau7,8, Peter Nürnberg12,14,16, Dieter Meschede17, 7 
Wolfgang Mühlbauer18, Nobuhiko Okamoto19, Vinod Varghese20, Rachel Irving20, 8 
Sabine Sigaudy21, Denise Williams22, S. Faisal Ahmed23, Carine Bonnard3, Mung Kei 9 
Kong3, Ilham Ratbi6, Nawfal Fejjal24, Meriem Fikri25, Siham Chafai Elalaoui6,26, 10 
Hallvard Reigstad27, Christine Bole-Feysot2,28, Patrick Nitschké2,29, Nicola Ragge22,30, 11 
Nicolas Lévy15,21, Gökhan Tunçbilek31, Audrey S.M. Teo32, Michael L. Cunningham33, 12 
Abdelaziz Sefiani6,26, Hülya Kayserili34, James M. Murphy7,8, Chalermpong 13 
Chatdokmaiprai35, Axel M. Hillmer32, Duangrurdee Wattanasirichaigoon36, Stanislas 14 
Lyonnet1,2,37, Frédérique Magdinier15, Asif Javed32#, Marnie E. Blewitt7,8#, Jeanne 15 
Amiel1,2,37#, Bernd Wollnik5,13#, Bruno Reversade3,4,34,38,39# 16 
 17 
1Laboratory of embryology and genetics of congenital malformations, Institut National 18 
de la Santé et de la Recherche Médicale (INSERM) UMR 1163, Institut Imagine, 19 
Paris, France. 20 
2Paris Descartes-Sorbonne Paris Cité University, Institut Imagine, Paris, France. 21 
3Human Genetics and Embryology Laboratory, Institute of Medical Biology, A*STAR, 22 
Singapore. 23 
4Institute of Molecular and Cell Biology, A*STAR, Singapore. 24 
5Institute of Human Genetics, University Medical Center Göttingen, Göttingen, 25 
Germany. 26 
6Centre de Génomique Humaine, Faculté de Médecine et de Pharmacie, Mohammed 27 
V University, Rabat, Morocco. 28 
7The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. 29 
2 
 
8The University of Melbourne, Melbourne, Australia. 30 
9Department of Human Genetics, Nagasaki University Graduate School of 31 
Biomedical Sciences, 1-12-4, Sakamoto, Nagasaki, Japan. 32 
10West of Scotland Regional Genetics Service, Laboratory Medicine Building, Queen 33 
Elizabeth University Hospital, Glasgow, UK. 34 
11Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, UK. 35 
12Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany. 36 
13Institute of Human Genetics, University of Cologne, Cologne, Germany. 37 
14Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, 38 
Germany. 39 
15Aix Marseille Université, INSERM, Génétique Médicale et Génomique 40 
Fonctionnelle (GMGF), UMR S_910, Marseille, France. 41 
16Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated 42 
Diseases (CECAD), University of Cologne, Cologne, Germany. 43 
17Praxis für Humangenetik, Cologne, Germany. 44 
18Plastische und Ästhetische Chirurgie, ATOS Klinik München, Munich, Germany. 45 
19Department of Medical Genetics, Osaka Medical Center and Research Institute for 46 
Maternal and Child Health, Izumi, Osaka, Japan. 47 
20Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK. 48 
21Département de Génétique Médicale, Hôpital Timone Enfant, Assistance Publique - 49 
Hôpitaux de Marseille, Marseille, France. 50 
22West Midlands Regional Genetics Service, Birmingham Women's NHS Foundation 51 
Trust, UK. 52 
23Developmental Endocrinology Research Group, University of Glasgow, RHC, 53 
Glasgow, UK. 54 
24Service de chirurgie plastique pédiatrique, Hôpital d'Enfants, CHU Ibn Sina, 55 
Mohammed V University, Rabat, Morocco. 56 
3 
 
25Service de neuroradiologie, Hôpital des Spécialités, CHU Ibn Sina, Mohammed V 57 
University, Rabat, Morocco. 58 
26Département de Génétique Médical, Institut National d'Hygiène, Rabat, Morocco. 59 
27Neonatal Intensive Care Unit, Children’s Department, Haukeland University 60 
Hospital, Bergen, Norway. 61 
28Genomic Platform, INSERM UMR 1163, Institut Imagine, Paris, France. 62 
29Bioinformatic Platform, INSERM UMR 1163, Institut Imagine, Paris, France. 63 
30Oxford Brookes University, Oxford, UK. 64 
31Hacettepe University Faculty of Medicine, Department of Plastic, Reconstructive 65 
and Aesthetic Surgery, Ankara, Turkey. 66 
32Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, 67 
A*STAR, Singapore. 68 
33University of Washington Department of Pediatrics, Division of Craniofacial 69 
Medicine and Seattle Children’s Hospital Craniofacial Center, Seattle, USA. 70 
34Department of Medical Genetics, Koç University, School of Medicine (KUSoM), 71 
Istanbul, Turkey.  72 
35Plastic and Maxillofacial Surgery, Department of Surgery, Faculty of Medicine 73 
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 74 
36Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine 75 
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 76 
37Département de Génétique, Hôpital Necker-Enfants Malades, Assistance Publique 77 
- Hôpitaux de Paris, Paris, France. 78 
38Department of Paediatrics, School of Medicine, National University of Singapore, 79 
Singapore. 80 
39Amsterdam Reproduction & Development, Academic Medical Centre & VU 81 
University Medical Center, Amsterdam, the Netherlands. 82 
*co-first authors 83 
4 
 
#co-last authors 84 
Correspondence should be addressed to: 85 
J.A. (jeanne.amiel@inserm.fr), B.W (bernd.wollnik@med.uni-goettingen.de) and B.R. 86 
(bruno@reversade.com). 87 
Keywords: 88 
Nasal, nose, arhinia, SMCHD1, Xenopus, HSP90, gain-of-function, Bosma 89 
Syndrome, facioscapulohumeral muscular dystrophy, FSHD2, chromatin, de novo, 90 
craniofacial, development, organogenesis, epigenetics.  91 
5 
 
 92 
Introductory paragraph 93 
Bosma arhinia microphthalmia syndrome (BAMS) is an extremely rare and striking 94 
condition characterized by complete absence of the nose with or without ocular 95 
defects. We report here that missense mutations in the extended ATPase domain of 96 
the epigenetic regulator SMCHD1 cause BAMS in all 14 cases studied. All mutations 97 
were de novo where parental DNA was available. Biochemical tests and in vivo 98 
assays in Xenopus embryos suggest that these mutations may behave as gain-of-99 
function alleles. This is in contrast to loss-of-function mutations in SMCHD1 that have 100 
been associated with facioscapulohumeral muscular dystrophy (FSHD) type 2. Our 101 
results establish SMCHD1 as a key player in nasal development and provide 102 
biochemical insight into its enzymatic function that may be exploited for development 103 
of therapeutics for FSHD.  104 
 105 
Main text 106 
Congenital absence of the nose (arhinia) is a rare and striking condition with less 107 
than 50 patients reported to date1. Arhinia is variably associated with absent 108 
paranasal sinuses, hypertelorism, microphthalmia, colobomas, nasolacrimal duct 109 
abnormalities, mid-face hypoplasia, high-arched palate, absent olfactory bulbs and 110 
defects of the reproductive axis in males. In its most severe presentation, consisting 111 
of nasal, ocular and reproductive defects, it is referred to as Bosma arhinia 112 
microphthalmia syndrome (BAMS) (OMIM 603457)1,2. Arhinia is presumed to result 113 
from a specific defect of the nasal placodes or surrounding neural crest-derived 114 
tissues during embryonic development, but a genetic cause has not been 115 
established. 116 
We investigated 14 unrelated individuals with isolated arhinia or a syndromic 117 
presentation compatible with BAMS (Fig. 1a-l, Supplementary Fig. 1 and 118 
Supplementary Table 1). Trio or quartet whole-exome sequencing (WES) for cases 119 
1, 2 and 9-12 led to the identification of de novo heterozygous missense mutations in 120 
the Structural Maintenance of Chromosomes Flexible Hinge Domain Containing 1 121 
(SMCHD1; NCBI Reference Sequence: NM_015295.2) gene in all six cases (Fig. 122 
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1m, Table 1 and Supplementary Table 2), which were confirmed by Sanger 123 
sequencing (Supplementary Fig. 2). Singleton WES for case 13 also identified a 124 
SMCHD1 mutation. We then performed Sanger sequencing of SMCHD1 in the 125 
remaining seven BAMS patients. Heterozygous missense mutations were identified 126 
in all. In total, 11 out of 14 variants were de novo, suggesting germline mutations in 127 
parental gametes, while in three cases parental DNA was not available (Fig. 1 and 128 
Table 1). None of the identified mutations have been reported in the ExAC, EVS or 129 
dbSNP144 databases (accessed via the UCSC browser, November 2016), all 130 
mutations affect highly conserved residues (Supplementary Fig. 3) and all are 131 
predicted damaging by PolyPhen-2 (Table 1). Remarkably, all 14 mutations are 132 
located in exons 3, 8-10, 12 and 13 of SMCHD1 (48 exons total); these exons code 133 
for the ATPase domain of SMCHD1 and an associated region immediately C-terminal 134 
(see further below). Notably, six of the 14 patients had mutations affecting three 135 
adjacent amino acids: Ala134, Ser135 and Glu136, while p.His348Arg and 136 
p.Asp420Val were identified in three and two independent patients respectively, 137 
suggesting possible hotspots (Fig. 1m). Mutations in SMCHD1 in arhinia patients 138 
have also been identified in an independent study that includes six of the cases 139 
analyzed here (cases 2, 4, 5, 6, 7 and 13; Shaw et al, accompanying manuscript).  140 
During craniofacial development, the olfactory placode ectoderm thickens and 141 
invaginates to form the olfactory epithelium within the nasal cavity, a process that 142 
depends on cross-talk between the placodal epithelium and the underlying cranial 143 
neural crest-derived mesenchyme3. For example, ablation of the nasal placode 144 
epithelium in chick embryos disrupts development of adjacent nasal skeletal 145 
elements4. We observed strong X-gal staining in the developing face of mouse 146 
embryos expressing lacz from the Smchd1 locus5, including in the nasal placodes 147 
and optic vesicles at E9.5 and nasal epithelium at E12.5 (Supplementary Fig. 4). 148 
Eurexpress in situ hybridization data indicates regional expression of Smchd1 in the 149 
nasal cavity at E14.5, while transcriptional profiling of post-natal olfactory epithelium 150 
demonstrated that Smchd1 is specifically expressed in immature olfactory sensory 151 
neurons6. These data are consistent with roles for SMCHD1 during early nasal 152 
development. Gonadotropin-releasing hormone (GnRH) neurons migrate from the 153 
olfactory placode along olfactory axon tracts to the hypothalamus, where they 154 
regulate reproductive hormone release from the pituitary gland. Defects of the 155 
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reproductive axis have occasionally been reported in males with arhinia1,2,7; we 156 
confirm this finding and also report pubertal delay or anomalies of menarche in all 157 
three post-pubertal age females in our series (Supplementary Table 1). The 158 
reproductive axis defects associated with arhinia are likely secondary to a defect in 159 
GnRH neuron production in, or migration from, the olfactory placode.  160 
Smchd1 was identified as a modifier of transgene silencing in mice and was 161 
subsequently shown to be involved in X chromosome inactivation, being required for 162 
CpG island (CGI) methylation on the inactive X (Xi), CGI-independent silencing of 163 
some X chromosome genes, and Xi compaction5,8–10. In addition, Smchd1 functions 164 
as an epigenetic repressor at various autosomal loci, with dysregulation of imprinted 165 
and monoallelically-expressed gene clusters observed in mutant mice9,11,12. A 166 
requirement for SMCHD1 in repair of DNA double-strand breaks has also been 167 
demonstrated13,14. Whereas female mice null for Smchd1 display midgestation 168 
lethality due to derepression of inactive X chromosome genes, male mutant mice 169 
display perinatal lethality of undescribed causes in certain strains or viability on the 170 
FVB/n background11. Strikingly, craniofacial abnormalities have not been 171 
documented in Smchd1 loss-of-function mice regardless of their sex. 172 
Recently, haploinsufficiency of SMCHD1 was reported as a cause of 173 
facioscapulohumeral muscular dystrophy (FSHD) type 2 (FSHD2) (OMIM 158901)15. 174 
FSHD has a prevalence of 1/20,000, with FSHD type 1 (FSHD1) and FSHD2 175 
accounting for ~95% and ~5% of cases, respectively16. FSHD results from 176 
pathogenic misexpression of the transcription factor DUX4 (encoded by an array of 177 
D4Z4 repeats on chromosome 4q) in skeletal muscle. In FSHD1 (OMIM 158900), 178 
D4Z4 repeat contraction leads to hypomethylation of the locus and derepression of 179 
DUX4 expression on a permissive haplotype (4qA) that harbors a stabilizing 180 
polyadenylation signal for DUX4 mRNA16,17. FSHD2 occurs in individuals harboring 181 
loss-of-function SMCHD1 mutations and the permissive 4qA allele, without the 182 
requirement for D4Z4 repeat contraction, although SMCHD1 mutations can also 183 
modify the severity of FSHD115,18. SMCHD1 is thought to function as a silencer at the 184 
4q locus via binding to the D4Z4 repeats15. Over 80 unique, putatively pathogenic 185 
SMCHD1 variants have been reported in FSHD2 patients (LOVD SMCHD1 variant 186 
database; see URLs). These mutations, which include clear loss-of-function alleles, 187 
occur throughout the protein, and are not clustered in specific domains. Several loss-188 
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of-function mutations have also been reported in ExAC (Fig. 1m), and over 60 189 
deletions affecting SMCHD1 have been reported in the DECIPHER database 190 
(available phenotypic information does not indicate arhinia). We analyzed the 191 
methylation status of D4Z4 repeats in peripheral blood leukocytes in BAMS patients 192 
by sodium bisulphite sequencing (Supplementary Table 3 and Supplementary 193 
Figs. 5-7). Although a trend for hypomethylation was noted for BAMS patients 194 
relative to controls or unaffected family members, depending on the site tested within 195 
D4Z4, some BAMS patients were normally methylated. A large variability in D4Z4 196 
methylation has also been observed in controls and FSHD patients19, and is not an 197 
absolute indicator of FSHD. Moreover, an important argument against BAMS and 198 
FSHD2 mutations acting in the same direction is the absence (to our knowledge) of 199 
BAMS and FSHD co-occurring in the same patient in the literature. None of the 200 
BAMS patients reported here have signs of muscular dystrophy, including both the 201 
individuals (2 and 12) older than the average age of FSHD2 onset of 26 years20, and 202 
none of the BAMS missense mutations identified here have been associated with 203 
FSHD2. 204 
Proteins of the SMC family are involved in chromatid cohesion, condensation of 205 
chromosomes and DNA repair. SMCHD1 is considered a non-canonical member of 206 
the family, with a C-terminal chromatin-binding hinge domain and an N-terminal 207 
GHKL (gyrase, Hsp90, histidine kinase, and MutL) ATPase domain21 (Fig. 1m). 208 
Potentially, SMCHD1 uses energy obtained from ATP hydrolysis to manipulate 209 
chromatin ultrastructure and interactions. Using small angle X-ray scattering, the 210 
purified Smchd1 ATPase domain and an adjacent C-terminal region (amino acids 211 
111-702 for the two regions combined; denoted “N-terminal region” in Fig. 1m) have 212 
been shown to adopt a structural conformation similar to Hsp9021. Consistent with 213 
this, the Hsp90 inhibitor radicicol decreased the ATPase activity of Smchd121,22. 214 
Mapping of the SMCHD1 amino acids mutated in BAMS and FSHD2 to the homology 215 
model of Smchd1 based on the Hsp90 crystal structure indicates that the major 216 
cluster of BAMS mutations (amino acids 134-136) is situated immediately N-terminal 217 
to Motif I, which is highly conserved among the GHKL-ATPases and participates in 218 
coordination of the Mg2+-ATP complex during ATP hydrolysis23 (Supplementary 219 
Figs. 3 and 8). The finding of other BAMS mutations in the region immediately C-220 
terminal to the ATPase domain supports the idea that this extended region has a 221 
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function intimately associated with that of the ATPase domain. Given that (i) loss-of-222 
function of SMCHD1 causes FSHD2, (ii) FSHD is not known to co-occur with arhinia, 223 
(iii) there are no visible craniofacial anomalies in Smchd1 null mice, (iv) the mutations 224 
in BAMS patients are clustered in the extended ATPase domain and (v) in contrast to 225 
SMCHD1 depletion13,14, BAMS mutations do not cause DNA damage response 226 
alterations or impaired non-homologous end joining (Supplementary Fig. 9), we 227 
hypothesized that the BAMS mutations may result in a gain- rather than a loss-of-228 
function of the SMCHD1 protein. To test this hypothesis, we conducted ATPase 229 
assays using the purified recombinant N-terminal region harboring BAMS or FSHD2 230 
mutations. Compared to wildtype, hydrolysis of ATP was increased for the N-terminal 231 
region containing the mutations p.Ala134Ser, p.Ser135Cys or p.Glu136Gly, strongly 232 
or slightly decreased for the FSHD2 mutations p.Tyr353Cys15 or p.Thr527Met18, 233 
respectively, and unchanged for the BAMS mutation p.Asp420Val (Fig. 2a-f). The 234 
half-maximal inhibitory concentration (IC50) of radicicol was similar for BAMS mutant 235 
and wildtype recombinant protein ATPase activities (Supplementary Fig. 10), 236 
suggesting that the mutants retain an intact ATP-binding site. These results suggest 237 
that BAMS-associated mutations elevate the catalytic activity of SMCHD1. 238 
We next sought to validate these biochemical results in vivo using full-length 239 
SMCHD1 protein. In Xenopus laevis, the expression of smchd1 begins zygotically, 240 
and rises steadily after gastrulation (Fig. 3a). Endogenous smchd1 is strongly 241 
enriched in the head region and the neural tube (Fig. 3b). To faithfully recapitulate 242 
this expression pattern, the two dorsal-animal blastomeres of 8-cell stage Xenopus 243 
embryos were micro-injected with 120 pg of capped mRNA encoding either wildtype 244 
or mutant human SMCHD1 (Fig. 3c). Each set of injected embryos was checked to 245 
ensure human SMCHD1 protein expression (Fig. 3g, Supplementary Fig. 11). Only 246 
tadpoles overexpressing SMCHD1 mRNA with BAMS mutations showed noticeable 247 
craniofacial anomalies (Fig. 3d-f, Supplementary Fig. 12), including microphthalmia 248 
and in severe cases, anophthalmia (Fig. 3f’). At 4 days post fertilization, 249 
quantification of the eye size showed a marked reduction in the eye diameter in 250 
tadpoles overexpressing BAMS mutants whereas tadpoles overexpressing wildtype 251 
SMCHD1 or p.Tyr353Cys, an FSHD2 mutation, were indistinguishable from control 252 
uninjected embryos (Fig. 3h). One of the BAMS mutants with phenotypic effects in 253 
this assay, p.Asp420Val, showed no change in ATPase activity in vitro (Fig. 2), 254 
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suggesting higher sensitivity of the in vivo assay. Whole mount in situ hybridization 255 
showed a decrease in the size of the eye and nasal placodes, marked by rx2a and 256 
six1 respectively, upon overexpression of a BAMS mutant (Fig. 3i,j). In contrast, 257 
migration of cranial neural crest, marked by twist1, was largely unaffected. 258 
Craniofacial anomalies were dose-dependent for both wildtype and BAMS mutant 259 
SMCHD1 injections, while overexpression of the FSHD2 mutant p.Tyr353Cys was 260 
without effect regardless of dose (Fig. 3k, Supplementary Fig. 12). The finding that 261 
wildtype SMCHD1, when overexpressed at a sufficiently high dose, acts in the same 262 
phenotypic direction as the BAMS mutants suggests that these mutants may at least 263 
in part act by augmenting the normal activity of the protein. These in vivo results, 264 
which partially recapitulate the microphthalmia and facial hypoplasia seen in severe 265 
BAMS patients, further support the notion that, in contrast to FSHD2 alleles, BAMS-266 
associated missense mutations may exhibit gain-of-function or neomorphic activity. 267 
We have not formally excluded the possibility that BAMS mutations may behave as 268 
dominant negatives through heterodimerization with wildtype protein. However, we 269 
believe this is unlikely, given the effects described above for overexpressed wildtype 270 
SMCHD1 and the finding that the isolated ATPase domain containing BAMS 271 
mutations can increase ATPase activity alone (Fig. 2). In addition, a human 272 
phenotype associated with a dominant negative mutation would be expected to 273 
present as a more severe disease than that associated with haploinsufficiency of the 274 
same gene, with at least some phenotypic overlap, but this is not the case for BAMS 275 
and FSHD.  276 
In conclusion, we have identified de novo missense mutations restricted to the 277 
extended ATPase domain of SMCHD1 as the cause of isolated arhinia and BAMS. It 278 
will be of great interest to explore the epistatic relationships between SMCHD1 and 279 
known regulators of nasal development, such as PAX6 and FGF and BMP signaling2, 280 
as well as to uncover other potential human-specific nasal regulators. Nose shape 281 
and size vary greatly between human populations and even more drastically among 282 
animal species, the elephant’s trunk being an extreme example. As such, it will be 283 
interesting to determine the role of SMCHD1 in controlling nose size from an 284 
evolutionary perspective.  285 
Given that loss-of-function mutations in SMCHD1 are associated with FSHD2, BAMS 286 
and FSHD2 represent a rare example of different functional classes of mutations in 287 
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the same gene leading to vastly different human disorders, in terms of the affected 288 
tissue and age of onset. As FSHD is caused in part by a loss of SMCHD1, the 289 
development of drugs that augment the expression or activity of SMCHD1 in affected 290 
muscles as a form of treatment is currently being pursued (for example, Facio 291 
Therapies; see URLs). Our identification of ATPase activity-augmenting mutations in 292 
SMCHD1 may inform gene therapy approaches, or in combination with future 293 
structural studies on the effect of these mutations on the ATPase domain, aid the 294 
design of drugs that induce SMCHD1 gain-of-function, for treatment of FSHD. 295 
Importantly for such an approach, the deleterious consequences of BAMS-associated 296 
SMCHD1 mutations appear restricted to a narrow window of human embryonic 297 
development.  298 
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 423 
Figure Legends 424 
Figure 1. SMCHD1 is mutated in Bosma arhinia microphthalmia syndrome and 425 
isolated arhinia. (a,b) Patient 1. (c,d) Patient 12. (e) Patient 3. (f) Patient 9. (g) 426 
Patient 10. (h) Patient 6. (i-l) Patient 11, with forehead implant in preparation for 427 
rhinoplasty (rectangular box in j), 6 months post-operation (k) and computed 428 
tomography scan of the skull pre-operation (l). Consent was obtained to publish 429 
patient images. (m) Position of BAMS missense mutations (black) and heterozygous 430 
loss-of-function mutations from ExAC (red) in SMCHD1. Short bars represent known 431 
missense (purple) and frameshift or nonsense (red) FSHD2 mutations. See 432 
Supplementary Fig. 3 for exact amino acids mutated in FSHD2 in the N-terminal 433 
region. 434 
 435 
Figure 2. Biochemical assays indicate that BAMS-associated mutations in SMCHD1 436 
show increased ATPase activity. (a-e) ATPase assays performed using recombinant 437 
protein encompassing amino acids 111-702 of Smchd1. (a) wildtype, (b) 438 
p.Ala134Ser, (c) p.Ser135Cys, (d) p.Glu136Gly, (e) p.Tyr353Cys. The amount of 439 
ADP produced at each protein concentration (0.1, 0.2, 0.4 and 0.6 μM) and ATP 440 
concentration (1, 2.5, 5 and 10 μM) was measured as described in the Online 441 
Methods. Data are displayed as mean ± s.d. of technical triplicates. Each plot is 442 
representative of at least two independent experiments using different batches of 443 
protein preparation. (f) Relative ATPase activities of the mutant proteins compared to 444 
wildtype protein. The amount of ADP produced by the mutant proteins was 445 
normalised to that of wildtype protein at each protein and substrate concentration as 446 
in (a-e). The normalised values are plotted as mean ± s.d. of biological replicates 447 
(n=44 for p.Ala134Ser, n=24 for p.Ser135Cys, n=32 for p.Glu136Gly, p.Asp420Val, 448 
p.Tyr353Cys and p.Thr527Met). In addition to analyzing normalised fold changes, for 449 
each mutant the mean of the triplicates at each protein/ATP concentration was 450 
compared to that of wildtype using the Wilcoxon matched-pairs signed rank test; 451 
apart from p.Asp420Val with a p-value of 0.1776 (non-significant), all the other 452 
mutants had a p-value <0.0001 (significant). 453 
 454 
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Figure 3. In vivo functional assays in Xenopus embryos suggest that BAMS 455 
mutations behave as gain-of-function alleles. (a) Expression of smchd1 relative to 456 
18S rRNA by qPCR. (b) In late tailbud stages, smchd1 expression is restricted to the 457 
head region and the neural tube. (c) To target the head structures, the dorsal-animal 458 
blastomeres of the 8-cell stage Xenopus embryo were injected with synthesized 459 
mRNAs (120 pg for all panels except k). These cells are fated to give rise to head 460 
structures as revealed by Dextran lineage tracing. (d-f’) Representative stage 45 461 
tadpoles injected with SMCHD1A134S display craniofacial anomalies and smaller eyes 462 
compared to control and SMCHD1WT injected tadpoles. Scale bar represents 0.3 mm. 463 
All pictures were taken at the same magnification. (g) Western blot of stage 12 464 
embryonic extracts from control and injected embryos shows exogenous human 465 
SMCHD1 expression. (h) The eye diameter is significantly reduced in embryos 466 
overexpressing BAMS mutants (blue) relative to SMCHD1WT overexpressing siblings 467 
(black), or embryos overexpressing an FSHD2 mutant (open circles). n = at least 15 468 
embryos for each condition. (i, j) In situ hybridization for rx2a, six1 and twist1, 469 
demarcating the eyes, placodes and neural crest respectively in embryos injected 470 
with SMCHD1WT (i) or SMCHD1A134S mRNA (j). Pictures are representative of n= 471 
9/10, 7/10, 10/10 embryos for each probe. Dotted lines outline nasal placodes in 472 
middle panels and the eye in the right panels. Numbers label streams of migrating 473 
cranial neural crest. Scale bar represents 0.2 mm (same magnification for each i to j 474 
comparison). (k) Measurements of eye diameter of Xenopus embryos injected with 475 
0.5 ng or 1 ng wildtype or BAMS mutant SMCHD1 mRNA show that SMCHD1 476 
overexpression causes dose-dependent craniofacial anomalies. Biological variation 477 
between clutches of tadpoles is seen in the data presented in panels h and k. n = 20 478 
embryos for each condition. Data are shown as means ± s.d.; p values were 479 
calculated by Kruskal-Wallis test followed by Dunn’s post test. 480 
 481 
Table 482 
Table 1. SMCHD1 mutations identified in patients 1-14. (1) NCBI Reference 483 
Sequence: NM_015295.2. (2) UniProtKB identifier: A6NHR9. Individuals also studied 484 
by Shaw et al are indicated with an asterisk. 485 
 486 
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Individua
l 
Geographic 
origin 
Nucleotide 
change (1) 
Amino acid 
change 
Predicted 
functional effect 
(Polyphen-2 
score) (2) 
Mutation origin 
1 Morocco c.407A>G p.Glu136Gly 0.999 de novo 
2* Germany c.403A>T p.Ser135Cys 1.000 de novo 
3 North Africa c.404G>A p.Ser135Asn 0.997 de novo 
4* Ireland c.403A>T p.Ser135Cys 1.000 de novo 
5* China c.1043A>G p.His348Arg 0.998 de novo 
6* Scotland c.1259A>T p.Asp420Val 0.877 de novo 
7* Japan c.1655G>A p.Arg552Gln 1.000 de novo 
8 Wales c.1552A>G p.Lys518Glu 0.976 unknown (parental DNA unavailable) 
9 Thailand c.1259A>T p.Asp420Val 0.877 de novo 
10 Thailand c.1025G>C p.Trp342Ser 0.999 de novo 
11 Turkey c.400G>T p.Ala134Ser 0.999 de novo 
12 Turkey c.400G>T p.Ala134Ser 0.999 de novo 
13* Norway c.1043A>G p.His348Arg 0.998 unknown (parental DNA unavailable) 
14 Ukraine c.1043A>G p.His348Arg 0.998 unknown (parental DNA unavailable) 
 487 
 488 
Online Methods 489 
Subjects 490 
In all cases informed consent was obtained from the families for genetic testing. For 491 
patients in Fig. 1, consent to publish photos was obtained.  492 
 493 
Whole-exome sequencing 494 
WES was conducted in accordance with approved institutional ethical guidelines 495 
(Comité de Protection des Personnes Ile-de-France II; Ethics Committee of the 496 
University Hospital Cologne, Germany; National University of Singapore Institutional 497 
Review Board). 498 
For trio whole-exome sequencing (WES) of case 1, Agilent SureSelect libraries were 499 
prepared from 3 μg of genomic DNA from each individual and sheared with a Covaris 500 
S2 Ultrasonicator. Exome capture was performed with the 51 Mb SureSelect Human 501 
All Exon kit V5 (Agilent technologies). Sequencing was carried out on a pool of 502 
barcoded exome libraries using a HiSeq 2500 instrument (Illumina), generating 100 + 503 
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100 bp paired-end reads. After demultiplexing, paired-end sequences were mapped 504 
to the reference human genome (GRCh37/hg19 assembly, NCBI) using Burrows-505 
Wheeler Aligner (BWA). The mean depth of coverage obtained for the three samples 506 
from case 1 was 123-, 149- and 150-fold, and 98% of the exome was covered by at 507 
least 15-fold. Downstream processing was performed using the Genome Analysis 508 
Toolkit (GATK)24, SAMtools25 and Picard. Variant calls were made with the GATK 509 
Unified Genotyper. All calls with read coverage ≤2-fold or a Phred-scaled SNP quality 510 
score of ≤20-fold were removed from consideration. Variant annotation was based on 511 
Ensembl release 7126. Variants were filtered against publicly available SNPs plus 512 
variant data from more than 7,000 in-house exomes (Institut Imagine). 513 
For trio WES of case 2, exonic and adjacent intronic sequences were enriched from 514 
genomic DNA using the NimbleGen SeqCap EZ Human Exome Library v2.0 515 
enrichment kit and probes were run on an Illumina HiSeq2000 sequencer at the 516 
Cologne Center for Genomics (CCG). Data analysis and filtering of mapped target 517 
sequences was performed with the “Varbank” exome and genome analysis pipeline 518 
v.2.1 (CCG) and data were filtered for high-quality (coverage of more than 6 reads, a 519 
minimum quality score of 10), rare (MAF < 0.5%) autosomal recessive and de novo 520 
variants.  521 
For cases 9 and 11 trios and 10 and 12 quartets, WES was performed at the 522 
Genome Institute of Singapore. Barcoded libraries were prepared for each individual 523 
by shearing 1ug of genomic DNA, followed by end-repair, A-tailing, adaptor ligation 524 
and PCR enrichment, then pooled and hybridized with NimbleGen SeqCap EZ 525 
Human Exome Library v3.0 probes. Captured DNA targets were purified and PCR 526 
amplified, then sequenced on Illumina HiSeq 2500 (cases 9 and 11) or HiSeq 4000 527 
(cases 10 and 12) sequencers. Variant calling was performed following GATK 528 
(v3.4.46) recommended best practices. Reads were mapped to GRCh37/hg19 using 529 
BWA and the aligned files pre-processed by Picard and GATK24,27,28. All samples 530 
were sequenced at mean coverage of 75X or higher. The variants were called using 531 
GATK HaplotypeCaller along with in-house exomes sequenced with the same 532 
chemistry. The variants were recalibrated, annotated and filtered against in-house 533 
data plus common publicly available databases. Each family was independently 534 
analyzed using Phen-Gen29 for de novo and recessive disease inheritance patterns. 535 
Variants with alternate allele frequency ≤ 10 or coverage ≤ 20 were not considered. 536 
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For case 13 WES, a library was prepared using the SureSelect XT Human All Exon 537 
V5 kit (Agilent Technologies) according to the manufacturer's instructions, followed 538 
by sequencing on a HiSeq2500 (Illumina). Raw data files were converted to FASTQ 539 
files with the bcl2fastq software package version 1.8.4 (Illumina). FASTQ files were 540 
mapped by Novoalign version 3 (Novocraft) to the hg19 human reference genome 541 
sequence. In this step, SNV information in dbSNP30 build 138 was used for base 542 
quality score recalibration. Marking of PCR duplicates and position-wise sorting was 543 
performed with Novosort version 3 (Novocraft). Calling of SNVs and small indels was 544 
performed using GATK24,27,28 version 3.4-46. A GATK workflow31 was used in which 545 
local realignment and variant calling were performed by IndelRealigner and 546 
HaplotypeCaller, respectively. Low quality SNV and small indel calls were removed 547 
using the following criteria: QD<2.0, MQ<40.0, FS>60.0, MQRankSum<-12.5, 548 
ReadPosRankSum<-8.0 for SNVs; QD<2.0, ReadPosRankSum<-20.0, FS>200.0 for 549 
small indels. SNVs and small indels were annotated with the ANNOVAR software 550 
package32 using the following datasets and programs: gene information from 551 
GENCODE33 (version 19); allele frequencies of the 1000 Genome Project34 (version 552 
August, 2015), ExAC (version 0.3; see URLs), EVS (release ESP6500SI-V2; see 553 
URLs) and an in-house database; and predictions of protein damage by PolyPhen-554 
235 and SIFT36 via dbNSFP37,38 (version 3.0).  555 
 556 
DNA methylation analysis 557 
Sodium bisulfite sequencing. DNA methylation was analyzed at single base 558 
resolution after sodium bisulfite modification, PCR amplification, cloning and Sanger 559 
sequencing. Briefly, 2 μg of genomic DNA was denatured for 30 minutes at 37°C in 560 
NaOH 0.4N and incubated overnight in a solution of sodium bisulfite 3M pH 5 and 10 561 
mM hydroquinone using a previously described protocol39. Converted DNA was then 562 
purified using the Wizard DNA CleanUp kit (Promega) following the manufacturer’s 563 
recommendations and precipitated by ethanol precipitation for 5 hours at -20°C. After 564 
centrifugation, DNA pellets were resuspended in 20 μL of water and stored at -20°C 565 
until use. Converted DNA was then amplified using primer sets (Supplementary 566 
Table 4) designed with the MethPrimer software40 avoiding the presence of CpGs in 567 
the primer sequence in order to amplify methylated and unmethylated DNA with the 568 
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same efficiency. Amplification was carried out using High Fidelity Taq polymerase 569 
(Roche) according to the manufacturer’s instructions. After initial denaturation at 570 
94°C for two minutes, amplification was done at 94°C for 20 seconds, 54°C for 30 571 
seconds and 72°C for one minute for 10 cycles, then at 94°C for 20 seconds, 54°C 572 
for 30 seconds, followed by an extension step of 4 minutes and 30 seconds for the 573 
first cycle and an increment of 30 seconds at each subsequent cycle for 25 cycles. At 574 
the end of the program, a final extension step at 72°C for 7 minutes was performed. 575 
PCR products were then purified using the Wizard SV gel and PCR Purification 576 
system (Promega), resuspended in 50 μl of water and cloned using the pGEM®-T 577 
Easy Vector cloning kit (Promega). Colonies were grown overnight at 37°C with 578 
ampicillin selection and randomly selected colonies were PCR amplified directly 579 
using T7 or SP6 primers. For each sample and region, at least ten randomly cloned 580 
PCR products were sequenced according to Sanger’s method by Eurofins MWG 581 
Operon (Ebersberg, Germany) with either SP6 or T7 primers. Sequences were 582 
analyzed using the BiQ Analyser software41 and the average methylation score was 583 
calculated as the number of methylated CpGs for the total number of CpGs in the 584 
reference sequence. 585 
Statistics and subjects. The average methylation level of each group of samples 586 
(FSHD2 patients carrying a SMCHD1 mutation, control individuals and BAMS 587 
patients and their relatives) was compared using the Kruskal-Wallis non-parametric 588 
multiple comparisons test followed by a Dunn’s comparison and Bonferroni 589 
correction, with α = 0.05. Control individuals (n=8) were healthy donors that have 590 
been previously reported42. The FSHD2 patients carrying a SMCHD1 mutation have 591 
been previously reported42,43 and comprise n=8 for the DR1 region and n=15 for each 592 
of the 5’ and Mid regions, while for the DR1 region 21 additional patients for whom 593 
sodium bisulfite sequencing data exists in the LOVD SMCHD1 variant database (see 594 
URLs) were included. 595 
 596 
Smchd1-Hsp90 structure modeling and multiple sequence alignment 597 
A homology model of the N-terminal region of Smchd1 was generated using the 598 
online server Phyre2 (Protein Homology/Analogy Recognition Engine 2)44. Protein 599 
sequence of 111-702 aa of mouse Smchd1 was submitted as the input sequence 600 
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and intensive modelling mode was selected. The second highest scoring model with 601 
the most sequence alignment coverage based on the crystal structure of yeast Hsp90 602 
(PDB: 2CG9) was elected for further evaluation. The model was visualized in 603 
PyMOL. The multiple sequence alignment was generated using CLUSTAL W45 (via 604 
the PBIL server) and ESPript 3.046. 605 
 606 
ATPase assays 607 
Cloning, expression and purification of recombinant mouse Smchd1 protein was 608 
performed as previously described21, and the primers used for cloning and 609 
mutagenesis are provided in Supplementary Table 5. The purity of the protein 610 
preparations was judged by migration of samples on 4-20% (w/v) Tris-Glycine 611 
reducing SDS/PAGE gels followed by staining with SimplyBlue SafeStain (Thermo 612 
Fisher Scientific, USA) (Supplementary Figure 13). The ATPase assay was 613 
performed with the Transcreener ADP2 fluorescence polarization assay kit (BellBrook 614 
Labs) as previously described21. Briefly, 10 µl reactions in triplicate were set up in 615 
384-well (low volume, black) plates, containing 7 µl reaction buffer (50 mM HEPES 616 
pH 7.5, 4 mM MgCl2 and 2 mM EGTA), 1 µl of recombinant Smchd1 111-702 aa 617 
protein at concentrations ranging from 0.1-0.6 µM or buffer control, 1 µl of radicicol or 618 
solvent control and 1 µl of 10 µM ATP substrate or nuclease-free water control. 619 
Hsp90 inhibitor radicicol (Sigma-Aldrich) was dissolved in 70% ethanol and further 620 
diluted to a final concentration ranging from 0.1 nM to 10 µM. A 12-point 10 µM 621 
ADP/ATP standard curve was set up in parallel. Reactions were incubated at room 622 
temperature for 1 hour in the dark before addition of 10 µl of detection mix (1X Stop & 623 
Detection Buffer B, 23.6 µg/ml ADP2 antibody) for a further hour of incubation. 624 
Fluorescence polarization readings were performed with an Envision plate reader 625 
(PerkinElmer Life Sciences) following the manufacturer’s instructions. The amount of 626 
ADP present in each reaction was estimated by using the standard curve following 627 
the manufacturer’s instructions.  628 
 629 
Mouse embryo dissection and X-gal staining 630 
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Mice were housed and mouse work approved under the Walter and Eliza Hall 631 
Institute of Medical Research Animal Ethics Committee approval (AEC 2014.026). 632 
Embryos were produced from C57BL/6 Smchd1gt/+ congenic strain sires mated with 633 
C57BL/6 dams, with embryo ages ranging from embryonic day 8.5 to embryonic day 634 
12.55. All embryos analyzed were female. No randomization or blinding was used 635 
during the experimental procedure. Embryos were briefly fixed in 2 % 636 
paraformaldehyde/0.2 % glutaraldehyde and stained in 1 mg/ml X-gal for several 637 
hours. Cryosections were cut at 12 μm. 638 
 639 
Xenopus embryological assays 640 
Xenopus laevis were used according to guidelines approved by the Singapore 641 
National Advisory Committee on Laboratory Animal Research. Protocols for 642 
fertilization, injections and whole mount in situ hybridization are available at the 643 
Reversade lab’s protocol website (see URLs). Human SMCHD1 (Origene) was 644 
cloned into expression vector pCS2+, linearized with NotI and transcribed with 645 
mMESSAGE mMachine SP6 transcription kit (Thermo Fisher). Transcribed mRNA 646 
was column purified and its concentration measured using a Nanodrop. The mRNA 647 
contains a poly A signal that allows for polyadenylation in vivo. To specifically target 648 
the cells destined to contribute to anterior head tissue, the two dorsal-animal 649 
blastomeres were injected at the 8-cell stage with the synthesized mRNA. Embryos 650 
were allowed to develop at room temperature until stage 45-46 (4 days post 651 
fertilization) and fixed. Eye diameter was measured using a Leica stereomicroscope 652 
with a DFC 7000T digital camera. No statistical method was used to predetermine 653 
sample size. No randomization or blinding was used. Embryos that died before 654 
gastrulation were excluded. Injections were performed on multiple clutches to reduce 655 
clutch-specific bias. mRNAs injected for Fig. 3k did not contain a poly A signal and 656 
were polyadenylated in vitro, hence requiring higher RNA concentration to produce a 657 
phenotype (in other panels in Fig. 3, and in Supplementary Figure 12, the mRNAs 658 
contained a poly A signal allowing polyadenylation in vivo). Embryonic extracts were 659 
prepared by lysing Stage 12 embryos in CelLytic Express (Sigma) on ice, followed by 660 
centrifugation to remove yolk proteins. Extracts were analyzed by Western blot with 661 
anti-SMCHD1 (Atlas HPA039441) and anti-GAPDH antibodies (clone 0411, Santa 662 
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Cruz). cDNA was made from RNA extracted from Xenopus laevis embryos of various 663 
stages using iScript reverse transcriptase (Bio-Rad). qPCR was performed using the 664 
following primers, xsmchd1_qPCR_F 5’- CAGTGGGTGTCATGGATGCT, 665 
xsmchd1_qPCR_R 5’- TCCATGGCTAGACCACTTGC, XL_18S_F 5’- 666 
GCAATTATTTCCCATGAACGA, XL_18S_R 5’- ATCAACGCGAGCTTATGACC. In 667 
situ hybridization probe for smchd1 was amplified from stage 20 cDNA using primers 668 
5’-CGAATGCAAAGTCCTTGGGC and 5’-GCATCCATGACACCCACTGA, cloned 669 
into pGEM-T, linearized and transcribed using DIG-labelling mix (Roche) according to 670 
manufacturer’s guidelines.  671 
 672 
DNA damage response assays 673 
Cell lines and cell cultures. XRCC4-deficient cells47 and primary fibroblast cell lines 674 
established from cases 1 and 2 were cultured in Dulbecco’s modified Eagle medium 675 
(DMEM, Gibco) supplemented with 10% fetal calf serum (FCS, Gibco), and 676 
antibiotics. Testing for mycoplasma contamination was negative. For H2AX 677 
activation, cells were either irradiated with 100 J/m2 UV-C or treated with 50 µM 678 
etoposide (Sigma-Aldrich, USA) for 1 hour. Drugs were then washed out, fresh media 679 
was added, and cells were incubated for 6 hrs and then subjected to Western blot 680 
analysis.  681 
Protein isolation and analysis. Cells were solubilized by using ice-cold RIPA buffer 682 
(10 mM Tris, pH: 8.0; 150 mM NaCl; 1 mM EDTA; 10 mM NaF; 1 mM Na3VO4; 10 µM 683 
Na2MoO4; 1% NP-40; 0.25% SDS; protease inhibitors P 2714 [Sigma-Aldrich, USA]). 684 
The total protein concentration of extracts was determined using the BCA Protein 685 
Assay Kit (Thermo Fisher Scientific, USA). 10 µg of total cell lysates were separated 686 
by 4-12 % SDS-PAGE (Invitrogen, Germany) and blotted onto nitrocellulose 687 
membranes (GE Healthcare, Germany). Protein detection was performed using 688 
antibodies specific for phosphorylation of H2AX at Ser139 (γH2AX) (clone 20E3, Cell 689 
Signaling Technology, USA). Anti-β-Actin antibodies were purchased from Sigma-690 
Aldrich (clone AC-74). Secondary antibodies conjugated to peroxidase (Santa Cruz 691 
Biotechnology Inc., USA) were used and blots were developed using an enhanced 692 
chemiluminescence system, ECL Plus (GE Healthcare), followed by detection on 693 
autoradiographic films. 694 
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Microhomology-mediated End-Joining (MMEJ) assay. The MMEJ assay using 695 
linearized pDVG94 plasmid was performed as previously described48. In brief, cells 696 
were transfected with 2 µg EcoRV/AfeI (Thermo Fisher Scientific, Germany; New 697 
England Biolabs, Germany)-linearized pDVG94 and extrachromosomal DNA was 698 
isolated 48 h after transfection. PCR analysis was performed, PCR products were 699 
digested using BstXI, separated by gel electrophoresis and visualized by ethidium 700 
bromide staining.  701 
 702 
 703 
Online Methods References 704 
24. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for 705 
analyzing next-generation DNA sequencing data. Genome Res 20, 1297–303 (2010). 706 
25. Li, H. et al. The Sequence Alignment/Map format and SAMtools. 707 
Bioinformatics 25, 2078–9 (2009). 708 
26. Flicek, P. et al. Ensembl 2013. Nucleic Acids Res 41, D48–55 (2013). 709 
27. DePristo, M. A. et al. A framework for variation discovery and genotyping using 710 
next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011). 711 
28. Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: 712 
the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinforma. Ed. 713 
Board Andreas Baxevanis Al 43, 11.10.1–33 (2013). 714 
29. Javed, A., Agrawal, S. & Ng, P. C. Phen-Gen: combining phenotype and 715 
genotype to analyze rare disorders. Nat. Methods 11, 935–937 (2014). 716 
30. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic 717 
Acids Res. 29, 308–311 (2001). 718 
31. Mishima, H., Sasaki, K., Tanaka, M., Tatebe, O. & Yoshiura, K.-I. Agile parallel 719 
bioinformatics workflow management using Pwrake. BMC Res. Notes 4, 331 (2011). 720 
32. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of 721 
genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 722 
(2010). 723 
33. Harrow, J. et al. GENCODE: the reference human genome annotation for The 724 
ENCODE Project. Genome Res. 22, 1760–1774 (2012). 725 
34. 1000 Genomes Project Consortium et al. A global reference for human genetic 726 
variation. Nature 526, 68–74 (2015). 727 
35. Adzhubei, I. A. et al. A method and server for predicting damaging missense 728 
mutations. Nat. Methods 7, 248–249 (2010). 729 
25 
 
36. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-730 
synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 731 
1073–1081 (2009). 732 
37. Liu, X., Jian, X. & Boerwinkle, E. dbNSFP: a lightweight database of human 733 
nonsynonymous SNPs and their functional predictions. Hum. Mutat. 32, 894–899 734 
(2011). 735 
38. Liu, X., Wu, C., Li, C. & Boerwinkle, E. dbNSFP v3.0: A One-Stop Database of 736 
Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site 737 
SNVs. Hum. Mutat. 37, 235–241 (2016). 738 
39. Magdinier, F. et al. Regional methylation of the 5’ end CpG island of BRCA1 is 739 
associated with reduced gene expression in human somatic cells. FASEB J. Off. 740 
Publ. Fed. Am. Soc. Exp. Biol. 14, 1585–1594 (2000). 741 
40. Li, L.-C. & Dahiya, R. MethPrimer: designing primers for methylation PCRs. 742 
Bioinforma. Oxf. Engl. 18, 1427–1431 (2002). 743 
41. Bock, C. et al. BiQ Analyzer: visualization and quality control for DNA 744 
methylation data from bisulfite sequencing. Bioinforma. Oxf. Engl. 21, 4067–4068 745 
(2005). 746 
42. Gaillard, M.-C. et al. Differential DNA methylation of the D4Z4 repeat in 747 
patients with FSHD and asymptomatic carriers. Neurology 83, 733–742 (2014). 748 
43. Gaillard, M.-C. et al. Segregation between SMCHD1 mutation, D4Z4 749 
hypomethylation and Facio-Scapulo-Humeral Dystrophy: a case report. BMC Med. 750 
Genet. 17, 66 (2016). 751 
44. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. & Sternberg, M. J. E. The 752 
Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 10, 753 
845–858 (2015). 754 
45. Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: improving the 755 
sensitivity of progressive multiple sequence alignment through sequence weighting, 756 
position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 757 
4673–4680 (1994). 758 
46. Robert, X. & Gouet, P. Deciphering key features in protein structures with the 759 
new ENDscript server. Nucleic Acids Res. 42, W320–324 (2014). 760 
47. Rosin, N. et al. Mutations in XRCC4 cause primary microcephaly, short stature 761 
and increased genomic instability. Hum. Mol. Genet. 24, 3708–3717 (2015). 762 
48. Verkaik, N. S. et al. Different types of V(D)J recombination and end-joining 763 
defects in DNA double-strand break repair mutant mammalian cells. Eur. J. Immunol. 764 
32, 701–709 (2002). 765 
 766 
 767 
26 
 
  768 
27 
 
 769 
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 771 
Supplementary Figure 1. Computed tomography and magnetic resonance imaging 772 
(MRI) in BAMS. (a-c) Controls and (d-f) patient 1 at four years. Patient 1 displays 773 
maxillary hypoplasia and absent nasal bones (d and e). Olfactory bulbs and sulci 774 
(labelled with red and white arrows, respectively, on the left side in the control in c) 775 
are absent in patient 1 (f). (g-i) patient 5, with right microphthalmia as shown by MRI 776 
(i). Skeletal imaging of patients 14 (j,k) and 11 (l) indicating midface hyploplasia.  777 
Supplementary Figure 2. BAMS pedigrees and Sanger sequencing chromatograms 778 
of SMCHD1 mutations. Individuals submitted for exome sequencing are indicated by 779 
a red asterisk. Note Sanger sequencing was unavailable for individual 13. 780 
Supplementary Figure 3. Multiple sequence alignment of vertebrate SMCHD1 781 
orthologues and yeast Hsp90. Residues mutated in BAMS are indicated by pink 782 
arrows. Residues mutated in FSHD are indicated by purple arrows. Hs, Homo 783 
sapiens; Mm, Mus musculus; Bt, Bos taurus; Gg, Gallus gallus; Md, Monodelphis 784 
domestica; Cm, Chelonia mydas; Xt, Xenopus tropicalis; Dr, Danio rerio; Sc, 785 
Saccharomyces cerevisiae. FSHD mutation reference: LOVD SMCHD1 variant 786 
database, http://databases.lovd.nl/shared/variants/SMCHD1/unique.  787 
Supplementary Figure 4. X-gal staining of mouse embryos expressing lacz from the 788 
Smchd1 locus. E, embryonic day. gt/+, embryos heterozygous for the Smchd1gt allele 789 
expressing lacz. +/+, wildtype embyros. hf, head folds. npl, nasal placode. ov, optic 790 
vesicle. npi, nasal pit. ne, nasal epithelium. f-i, coronal sections. r and s, transverse 791 
sections. An asterisk in panel p indicates deep nasal staining. 792 
Supplementary Figure 5. Sodium bisulfite sequencing in BAMS patients (individuals 793 
1-6). The position of the three different regions analyzed within D4Z4 is indicated 794 
above the corresponding column (left, DR1; middle, 5’; right, Mid). For each sample, 795 
at least 10 cloned DNA molecules were analyzed by Sanger sequencing. Each 796 
histogram column corresponds to a single CpG. Black corresponds to the global 797 
percentage of methylated CpGs and white to the global percentage of unmethylated 798 
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CpGs. The percentage of methylated CpGs among the total CpGs in each individual 799 
analyzed are given in Supplementary Table 3. 800 
Supplementary Figure 6. Sodium bisulfite sequencing in BAMS patients (individuals 801 
8-11 and 14). See legend of Supplementary Figure 5 for further information. 802 
Supplementary Figure 7. Comparison of D4Z4 methylation in BAMS or FSHD2 803 
patients, BAMS patient relatives and controls. Distribution of methylation for the three 804 
different regions within the D4Z4 sequence (DR1, 5’ and Mid) in control individuals, 805 
patients with FSHD2 carrying a SMCHD1 mutation and BAMS patients and their 806 
relatives. Means ± SEM are shown. A Kruskal-Wallis multiple comparisons test was 807 
performed, followed by a Dunn’s test and Bonferroni correction, with α = 0.05. ***, 808 
p<0.0001 ; **, p<0.001 ; *, p<0.05. Blue points indicate outliers. Red crosses indicate 809 
medians. The level of methylation is statistically significantly different between 810 
controls and FSHD2 patients for the DR1 (** ; p<0.001) and the 5’ (*** ; p< 0.0001) 811 
regions. The level of methylation is significantly different between controls and BAMS 812 
patients for the 5’ region (*, p<0.05) and between BAMS patients and their relatives 813 
for the DR1 (*, p<0.05) and 5’ (**, p<0.001) regions.  814 
Supplementary Figure 8. Smchd1 structure modelling, based on the structure of 815 
Hsp90. Residues mutated in BAMS are indicated in pink. Residues mutated in FSHD 816 
are indicated in purple. 817 
Supplementary Figure 9. Fibroblasts derived from BAMS patients show no defects 818 
in NHEJ or in H2AX activation. (a) A microhomology mediated end joining (MMEJ) 819 
assay was performed on wildtype (WT), XRCC4-deficient and case 1 and 2 820 
fibroblasts. Whereas XRCC4-deficient fibroblasts show multiple smaller DNA bands 821 
after BstXI digestion indicating defects in NHEJ-mediated DNA repair and leading to 822 
preferential use of MMEJ-mediated DNA double strand repair, BAMS patient 823 
fibroblasts show no defects in NHEJ-mediated DNA repair pathways compared to 824 
wildtype. (b) Western blot analysis of UV- and etoposide-induced phosphorylation of 825 
H2AX at Ser139 (γH2AX). Wildtype fibroblasts (WT) and fibroblasts derived from 826 
cases 1 and 2 were treated with UV-C (UV) or etoposide (Eto) or left untreated as a 827 
control (-). Cells were lysed and subjected to Western blot analysis with an antibody 828 
against γH2AX. Equal protein loading was confirmed by reprobing of the membrane 829 
29 
 
with an antibody against β-Actin. Wildtype and BAMS patient fibroblasts did not show 830 
significant differences in H2AX activation. 831 
Supplementary Figure 10. ATPase assays performed using recombinant wildtype or 832 
mutant Smchd1 protein in the presence of radicicol. Data are displayed as mean ± 833 
s.d. of technical triplicates. The data are representative of at least two independent 834 
experiments using different batches of protein preparation.  835 
Supplementary Figure 11. Full-length Western blot of the cropped blot image in Fig. 836 
3g. 837 
Supplementary Figure 12. SMCHD1 overexpression in Xenopus causes dose-838 
dependent craniofacial anomalies. (a,b) Measurements of eye diameter of Xenopus 839 
embryos injected with 240 pg (a) or 500 pg (b) SMCHD1 mRNA. Y353C is an FSHD2 840 
mutation. n = at least 20 embryos for each condition. (c-f) Representative Xenopus 841 
embryos injected with 500 pg of WT or FSHD2 mutant SMCHD1 or 120 pg of BAMS 842 
mutant mRNA show varying degrees of craniofacial abnormalities as compared to 843 
uninjected control tadpoles at 4 days post fertilization. Data are shown as means ± 844 
s.d.; p values were calculated by Kruskal-Wallis test followed by Dunn’s post test. 845 
n.s. not significant.  846 
Supplementary Figure 13. Purity of proteins used for ATPase assays. Purified 847 
recombinant wild type or mutant proteins were resolved by 4-20% (w/v) Tris-Glycine 848 
reducing SDS/PAGE and were stained with SimplyBlue SafeStain. Protein quantities 849 
loaded: left gel, 1.4 μg; middle gel, 1.05 μg; right gel, 0.7 μg. Molecular weight (MW) 850 
markers are as indicated on the left-hand side. 851 
Supplementary Table 1. Clinical features of 14 BAMS patients. 852 
Supplementary Table 2. Exome variant filtering for cases 1, 2 and 9-13. 853 
Supplementary Table 3. DNA methylation analysis in BAMS probands and family 854 
members. Three different regions within the D4Z4 macrosatellite repeat were 855 
analyzed: DR1 (as described in Hartweck et al., Neurology, 80, 392-399 (2013)); 5’ 856 
and Mid (as described in Gaillard et al., Neurology, 83, 733-742 (2014)). The Mid 857 
region corresponds to the DUX4 promoter. % M+ indicates the percentage of 858 
methylated CpGs among the total CpGs for a given region. X indicates samples that 859 
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were not analyzed. All samples were obtained from peripheral blood leukocytes 860 
except for individual 4’s brother and sister and individual 14, which were from saliva. 861 
Supplementary Table 4. Primers used for sodium bisulfite PCR. 862 
Supplementary Table 5. Primers used for cloning and mutagenesis of recombinant 863 
murine Smchd1. 864 
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Supplementary Figure 1 
Computed tomography and magnetic resonance imaging (MRI) in BAMS. 
(a-c) Controls and (d-f) patient 1 at four years. Patient 1 displays maxillary hypoplasia and absent nasal bones (d and e). Olfactory 
bulbs and sulci (labelled with red and white arrows, respectively, on the left side in the control in c) are absent in patient 1 (f). (g-i) 
patient 5, with right microphthalmia as shown by MRI (i). Skeletal imaging of patients 14 (j,k) and 11 (l) indicating midface hyploplasia. 
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Supplementary Figure 2 
BAMS pedigrees and Sanger sequencing chromatograms of SMCHD1 mutations. 
Individuals submitted for exome sequencing are indicated by a red asterisk. Note Sanger sequencing was unavailable for individual 13. 
5 
 
 
6 
 
Supplementary Figure 3 
Multiple sequence alignment of vertebrate SMCHD1 orthologues and yeast Hsp90. 
Residues mutated in BAMS are indicated by pink arrows. Residues mutated in FSHD are indicated by purple arrows. Hs, Homo 
sapiens; Mm, Mus musculus; Bt, Bos taurus; Gg, Gallus gallus; Md, Monodelphis domestica; Cm, Chelonia mydas; Xt, Xenopus 
tropicalis; Dr, Danio rerio; Sc, Saccharomyces cerevisiae. FSHD mutation reference: LOVD SMCHD1 variant database, 
http://databases.lovd.nl/shared/variants/SMCHD1/unique. 
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Supplementary Figure 4 
X-gal staining of mouse embryos expressing lacz from the Smchd1 locus. 
E, embryonic day. gt/+, embryos heterozygous for the Smchd1gt allele expressing lacz. +/+, wildtype embyros. hf, head folds. npl, nasal 
placode. ov, optic vesicle. npi, nasal pit. ne, nasal epithelium. f-i, coronal sections. r and s, transverse sections. An asterisk in panel p 
indicates deep nasal staining. 
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Supplementary Figure 5 
Sodium bisulfite sequencing in BAMS patients (individuals 1-6). 
The position of the three different regions analyzed within D4Z4 is indicated above the corresponding column (left, DR1; middle, 5’; 
right, Mid). For each sample, at least 10 cloned DNA molecules were analyzed by Sanger sequencing. Each histogram column 
corresponds to a single CpG. Black corresponds to the global percentage of methylated CpGs and white to the global percentage of 
unmethylated CpGs. The percentage of methylated CpGs among the total CpGs in each individual analyzed are given in 
Supplementary Table 3. 
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Supplementary Figure 6 
Sodium bisulfite sequencing in BAMS patients (individuals 8-11 and 14). 
See legend of Supplementary Figure 5 for further information. 
13 
 
 
Supplementary Figure 7 
Comparison of D4Z4 methylation in BAMS or FSHD2 patients, BAMS patient relatives and controls. 
Distribution of methylation for the three different regions within the D4Z4 sequence (DR1, 5’ and Mid) in control individuals, patients with 
FSHD2 carrying a SMCHD1 mutation and BAMS patients and their relatives. Means ± SEM are shown. A Kruskal-Wallis multiple 
comparisons test was performed, followed by a Dunn’s test and Bonferroni correction, with α = 0.05. ***, p<0.0001 ; **, p<0.001 ; *, 
p<0.05. Blue points indicate outliers. Red crosses indicate medians. The level of methylation is statistically significantly different 
between controls and FSHD2 patients for the DR1 (** ; p<0.001) and the 5’ (*** ; p< 0.0001) regions. The level of methylation is 
significantly different between controls and BAMS patients for the 5’ region (*, p<0.05) and between BAMS patients and their relatives 
for the DR1 (*, p<0.05) and 5’ (**, p<0.001) regions. 
14 
 
 
Supplementary Figure 8 
Smchd1 structure modelling, based on the structure of Hsp90. 
Residues mutated in BAMS are indicated in pink. Residues mutated in FSHD are indicated in purple. 
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Supplementary Figure 9 
Fibroblasts derived from BAMS patients show no defects in NHEJ or in H2AX activation. 
(a) A microhomology mediated end joining (MMEJ) assay was performed on wildtype (WT), XRCC4-deficient and case 1 and 2 
fibroblasts. Whereas XRCC4-deficient fibroblasts show multiple smaller DNA bands after BstXI digestion indicating defects in NHEJ-
mediated DNA repair and leading to preferential use of MMEJ-mediated DNA double strand repair, BAMS patient fibroblasts show no 
defects in NHEJ-mediated DNA repair pathways compared to wildtype. (b) Western blot analysis of UV- and etoposide-induced 
phosphorylation of H2AX at Ser139 (γH2AX). Wildtype fibroblasts (WT) and fibroblasts derived from cases 1 and 2 were treated with 
UV-C (UV) or etoposide (Eto) or left untreated as a control (-). Cells were lysed and subjected to Western blot analysis with an antibody 
against γH2AX. Equal protein loading was confirmed by reprobing of the membrane with an antibody against β-Actin. Wildtype and 
BAMS patient fibroblasts did not show significant differences in H2AX activation. 
16 
 
 
Supplementary Figure 10 
ATPase assays performed using recombinant wildtype or mutant Smchd1 protein in the presence of radicicol. 
Data are displayed as mean ± s.d. of technical triplicates. The data are representative of at least two independent experiments using 
different batches of protein preparation. 
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Supplementary Figure 11 
Full-length Western blot of the cropped blot image in Fig. 3g. 
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Supplementary Figure 12 
SMCHD1 overexpression in Xenopus causes dose-dependent craniofacial anomalies. 
(a,b) Measurements of eye diameter of Xenopus embryos injected with 240 pg (a) or 500 pg (b) SMCHD1 mRNA. Y353C is an FSHD2 
mutation. n = at least 20 embryos for each condition. (c-f) Representative Xenopus embryos injected with 500 pg of WT or FSHD2 
mutant SMCHD1 or 120 pg of BAMS mutant mRNA show varying degrees of craniofacial abnormalities as compared to uninjected 
control tadpoles at 4 days post fertilization. Data are shown as means ± s.d.; p values were calculated by Kruskal-Wallis test followed 
by Dunn’s post test. n.s. not significant. 
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Supplementary Figure 13 
Purity of proteins used for ATPase assays. 
Purified recombinant wild type or mutant proteins were resolved by 4-20% (w/v) Tris-Glycine reducing SDS/PAGE and were stained 
with SimplyBlue SafeStain. Protein quantities loaded: left gel, 1.4 µg; middle gel, 1.05 µg; right gel, 0.7 µg. Molecular weight (MW) 
markers are as indicated on the left-hand side.  
Individual Sex Age Nose Eyes Other craniofacial Reproductive system Growth Psychomotor development Other Previous publication
1 male 5 years Complete arhinia.
Microcorneas and corneal 
opacities. Deformed pupils. 
Globulous cataract 
(bilateral). Ectopic lens (R). 
Ectopic pupil (L). Primitive 
vitreous persistence (R). 
Bilateral microphthalmia. 
Bilateral esotropia. Limited 
visual acuity. Hypoplasia of 
the optic nerves.
Hypertelorism. Absence of the 
nasal cavity, nasal bones and of 
cartilaginous nasal structures. 
Agenesis of the maxillary, frontal, 
sphenoidal and ethmoidal sinuses. 
Hypoplasia of the ethmoid and 
maxilla. Preauricular sinus (R). Normal. Normal. Normal.
Absence of olfactory bulbs and 
sulci. no
2 female 28 years Complete arhinia.
Microphthalmia. Bilateral 
strabismus.
Hypertelorism. High arched palate. 
Choanal atresia. Absent 
nasolacrimal ducts.
Delayed menstruation 
requiring hormone 
induction at puberty.  Normal. Normal.
Muhlbauer et al, 1993, Plast Reconstr Surg 
and Sato et al, 2007, AJMG (case C)
3 male 4 years Complete arhinia. Normal.
Absence of the nasal cavity, the 
nasal spine of the frontal bone,the 
nasal bones, the vomer and the 
conchae. Midline cleft of the 
cribriform plate. Absence of central 
incisor(s). NA Normal. Normal. Olfactory bulb agenesis. no
4 female 3 years Complete arhinia.
Eye coloboma (L) involving 
the disc, lens and retina. 
Cataract.
Bilateral bony choanal atresia. 
Hypoplasia of maxillary sinuses. 
Mild hypertelorism. Normal. Delayed. Normal.
Small apical ventricular septal 
defect.
Courtney et al, 2014, Arch Dis Child Fetal 
Neonatal Ed
5 male 7 years Arhinia.
Microphthalmia (R) with 
severe visual impairment, 
microphthalmia (L) with 
sclerocornea. 
Midface hypoplasia, bifid philtral 
region, small mouth, high palate 
with soft palate cleft, small 
preauricular pit (R), hypoplasia of 
maxillary sinus, nuchal oedema, 
hypoplasia of nasolacrimal duct (L).
Micropenis, normal 
testes, 
hypogonadotropic 
hypogonadism.
At birth, 
weight 
25th%, head 
circumferen
ce 75th%, 
length 
>99th%. 
Growth 
delayed; 
weight and 
height just 
over 9th%. Severe learning difficulties.
Moderate persistent ductus 
arteriosus, and tiny persistent 
foramen ovale at birth. no
6 male 14 years Complete arhinia.
Chronic epiphora. Cataract 
(R).
Facial asymmetry. Mid‐face 
hypoplasia.
Micropenis. Bilateral 
undescended testes. 
Low gonadatropins;  has 
been started on 
testosterone 
supplements.
Height 
delayed. 
Weight and 
OFC normal. Learning difficulties.
Transaminitis associated with 
hypoalbuminaemia and 
peripheral oedema, with 
diffuse echogenic liver 
consistent with fatty 
infiltration. Bronchiectasis. 
Fixed flexion contractures at 
the hips and knees. no
7 male 13 years Complete arhinia.
Bilateral microphthalmia. 
Coloboma of the iris.
Midface hypoplasia. High arched 
palate. Hypertelorism. Absent 
nasolacrimal ducts.
Micropenis. 
Hypogonadotropic 
hypogonadism.
Normal at 9 
years.
Autistic and aggressive 
behavior. Psychomotor 
developmental quotient  
moderately delayed. Needs 
special education program 
at school.
Generalized seizures. Agenesis 
of the olfactory bulbs. Sato et al, 2007, AJMG (case B)
8 female 4 years
Complete arhinia 
(small pit to the left of 
the columella, no nasal 
airway).
Bilateral microphthalmia. 
Short palpebral fissures. 
Blepharophimosis. Bilateral 
corneal opacities. Upbeat 
nystagmus with poor 
fixation following reflexes. 
Flash Visual Evoked 
Potential evident 
bilaterally, but no 
consistent evidence of 
patent Visual Evoked 
Potential, suggesting visual 
impairment.
High arched palate. Hypertelorism. 
Bilateral complete absence of the 
lacrimal apparatus. Absence of 
nasal cavity and ethmoid sinuses. Normal. Normal. Normal.
Floor of the anterior cranial 
fossa is deficient anteriorly, 
with an encephalocele. no
9 male 3 years Complete arhinia. Normal.
Telecanthus. Downward slant 
palpebral fissure. Midface 
hypoplasia. Obstruction of 
nasolacrimal passage. Absence of 
nasal cavity, nasal bone and 
anterior soft tissue. High arched 
palate. Paramedian notch of the 
upper lip (bilateral). 
Nonpneumatization of the 
maxillary, sphenoid and ethmoid 
sinuses. Slim penis. Normal. Normal.
Bilateral olfactory bulb 
agenesis. no
10 female 3 years
Partial arhinia (patency 
of left nostril but 
complete obstruction 
of left posterior nare). Normal.
Telecanthus. Upward slant 
palpebral fissure. Midface 
hypoplasia. Obstruction of 
nasolacrimal passage. Nasal bone 
hypoplasia. High arched palate. 
Nonpneumatization of the 
maxillary, sphenoid and ethmoid 
sinuses. Normal. Normal. Normal. Olfactory bulb agenesis (L). no
11 female 9 years Complete arhinia. Normal.
Telecanthus. High arched palate. 
Agenesis of nasal bone. Absence of 
nasal cavity. Midface hypoplasia. Normal. Normal. Normal. Atrial septal defect. no
12 female 26 years Complete arhinia.
Bilateral microphthalmia. 
Ectopic iris. Vision loss (can 
only see light).
Hypertelorism. Posterior cleft  
palate. Gingival cleft of lower arch. 
Cleft lower lip (operated). Cleft 
mandibula. Underdeveloped 
superior ear pinnae, auricular pit 
(R). Absent auditory canal (R). CT: 
absence of external auditory  
canals. Absence of nasal cavity, 
nasal bone and anterior soft tissue. 
Midface hypoplasia. Obstruction of 
nasolacrimal passage.
Hypoplastic labia 
majora. No menarche or 
secondary sex 
development.
 Tall and 
strong build.  
Severe psychomotor  
retardation. Walked at  4.5 
years, talked with two word 
sentences at the age of 4 
years then lost vocabulary. 
Has prominent articulation 
defect. Never had toilet 
training. Has sleep disorder. 
Stereotypic movements. 
Anxious, aggressive and non‐
cooperative.
Bilateral olfactory bulb 
agenesis. no
13 female 17 years Complete arhinia.
Bilateral coloboma of the 
iris.
High arched palate. Slight 
hypertelorism. Absence of 
paranasal sinuses, nasal bones, 
cribriform plate and septal 
structures. Maxillary hypoplasia. 
Nasolachrymal duct atresia.
Delayed puberty with 
low gonadotropins; has 
been started on 
estrogen. Normal. Normal.
Absence of olfactory bulbs and 
sulci. Fused medial orbital and 
rectus gyri.
Olsen et al, 2001, Pediatr Radiol and Sato et 
al, 2007, AJMG (case D)
14 female 4 years Complete arhinia.
Bilateral microphthalmia. 
Iris anatomy unknown. 
Hypertelorism. Coarse calcifications  
along the medial aspect of the globes 
bilaterally. Narrow high arched palate.  
Choanal and mastoid air cell atresia 
bilaterally with a dysmorphic and 
expansile appearance of the greater 
wing of the sphenoid bone and 
infratemporal surface of the maxillary 
bone bilaterally. Absent paranasal 
sinuses. Central cleft between the 
dysmorphic maxilla. Absent cribriform 
plate and crista galli. No identified 
osseous plate between the non‐
pneumatized central nasal passage and 
the frontal lobes. External genitalia 
normal.
Growth 
deficiency. 
Thought to 
have 
nutritional 
deficiency. 
BMI 13.7
Significant psychomotor 
delays. Thought to be 
related to lack of 
environmental stimuli.
No evidence of olfactory bulbs 
on CT scan. no
R, right‐sided. L, left‐sided. NA, information not available. OFC, occipital frontal circumference.
FILTER
Exome strategy
Total substitutions, deletions, 
insertions
Frequency <1% in public SNP 
databases, in‐house exomes*
de novo recessive de novo recessive de novo recessive de novo recessive de novo recessive de novo recessive heterozygous homozygous
Essential splicing, non‐
synonymous, frameshift and stop 
mutations**
SMCHD1, 
SLC17A9, 
CAPN7, 
ERC2
CACHD1, 
SH2D4B, 
BMPR1A, 
FOXC1
SMCHD1, 
AFAP1L1, 
GPR63
KIF26B, 
ITIH4, 
AXIN1, 
KLRC3
CYP21A2, 
WDR89, 
SMCHD1, 
MUC20,  
KRTAP1‐1
FAM35A, 
FAM9B, 
ZNF81, 
ZNF645, 
MTUS1, 
HPRT1, 
GFPT2
CYP21A2, 
HLA‐DRB1, 
SCNN1B, 
SMCHD1, 
FOXK2, 
FAM182B, 
TAS2R30, 
CBWD1, 
PRSS3
CDH23, 
LANCL1, 
TRERF1, 
ZNF136, 
AGAP5
SMCHD1, 
ZMYM2, 
CRIPAK
RPS6KC1, 
MEFV, 
MUC16 SMCHD1
BCHE, 
TGM2, 
GPR35
426 genes 
including 
SMCHD1 12 genes
Predicted damaging by Polyphen 
and/or Sift
SMCHD1, 
SLC17A9, 
ERC2
CACHD1, 
SH2D4B, 
FOXC1
SMCHD1, 
GPR63
ITIH4,  
AXIN1
CYP21A2, 
WDR89, 
SMCHD1
FAM35A, 
FAM9B, 
ZNF81, 
ZNF645, 
MTUS1, 
HPRT1
CYP21A2, 
HLA‐DRB1, 
SCNN1B, 
SMCHD1, 
FOXK2, 
FAM182B LANCL1 SMCHD1 RPS6KC1 SMCHD1 BCHE, TGM2
210 genes 
including 
SMCHD1 ANKRD20A4
Genes harbouring de novo or 
rare recessive variants predicted 
to affect protein function in 
more than one patient
*for patient 1, in‐house exomes = 
more than 7,000 exomes 
performed at the Institut Imagine
**for Patients 9‐12 Phen‐Gen 
filters were also applied
NA, not available.
Quartet SingletonTrio Trio Trio Quartet Trio
Patient 13
VARIANTS/GENES
322,818 variants
23,414 variants
Patient 1 Patient 2 Patient 9 Patient 10 Patient 11 Patient 12
1,664 1,562 1,355 1,492
114,499 variants NA 67,374 67,093 67,360 67,746
de novo recessive
SMCHD1 (6 patients), 
CYP21A2 (2 patients)
1,598 variants 525 variants
 Sample ID Gender Clinical Status Mutation 
DR1 5’ Mid 
% M+ % M+ % M+ 
Indiv-1 M Proband E136G 5 54 73 
Indiv-1 father M CTRL -  69 72 64 
Indiv-1 mother F CTRL -  56 73 73 
Indiv-2 F Proband S135C 19 48 60 
Indiv-2 mother F CTRL -  74 86 71 
Indiv-2 father M CTRL -  45 77 X 
Indiv-3 M Proband S135N 22 44 62 
Indiv-3 mother F CTRL -  58 82 83 
Indiv-3 father M CTRL -  62 75 75 
Indiv-4 F Proband S135C 21 44 70 
Indiv-4 father M CTRL -  44 69 79 
Indiv-4 mother F CTRL - 31 50 X 
Indiv-4 sister F CTRL - 18 62 X 
Indiv-4 brother M CTRL - 26 70 X 
Indiv-5 M Proband H348R 66 56 58 
Indiv-6 M Proband D420V 19 41 68 
Indiv-6 father M CTRL - 50 67 50 
Indiv-6 mother F CTRL - X 87 69 
Indiv-8 F Proband K518E 33 74 71 
Indiv-14 F Proband H348R 35 49 63 
Indiv-9 M Proband D420V 25 50 66 
Indiv-9 father M CTRL - 29 74 75 
Indiv-9 mother F CTRL - 76 81 69 
Indiv-11 father M CTRL - 50 72 71 
Indiv-11 mother F CTRL - 80 81 69 
Indiv-11 F Proband A134S 17 63 68 
Indiv-10 F Proband W342S 54 69 X 
Indiv-10 mother F CTRL - 27 50 73 
Indiv-10 sister F CTRL - 86 75 68 
 
Supplementary Table 3. DNA methylation analysis in BAMS probands and family members. 
Three different regions within the D4Z4 macrosatellite repeat were analyzed: DR1 (as 
described in Hartweck et al., Neurology, 80, 392-399 (2013)); 5’ and Mid (as described in 
Gaillard et al., Neurology, 83, 733-742 (2014)). The Mid region corresponds to the DUX4 
promoter. % M+ indicates the percentage of methylated CpGs among the total CpGs for a 
given region. X indicates samples that were not analyzed. All samples were obtained from 
peripheral blood leukocytes except for individual 4’s brother and sister and individual 14, 
which were from saliva. 
  
  
 
Name 
Size 
(bp) 
# of 
CpG 
Forward Reverse 
DR1 255 31 GAAGGTAGGGAGGAAAAG ACTCAACCTAAAAATATACAATCT 
5’ 275 21 AAATATGTAGGGAAGGGTGTAAGTT GGAGAGAGGGTTTGGTATATTTAAG 
Mid 354 31 ATTCATGAAGGGGTGGAGCCT CAGAGAACGGCTGGCCCAGGCCAT 
 
Supplementary Table 4. Primers used for sodium bisulfite PCR. 
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Supplementary Table 5. Primers used for cloning and mutagenesis of recombinant murine 
Smchd1. 
 
 
